CXCL1 and bone cancer: In another preclinical study on bone cancer pain (BCP), intrathecal liquiritin 8 dose-dependently ameliorated bone cancer-induced mechanical allodynia and inhibited BCP-induced elevated astrocytic activation.41 In addition, liquiritin 8 inhibited BCP-induced chemokine (CXCL-1) upregulation in spinal astrocytes and attenuated BCP-induced chemokine (CXCR-2) upregulation in spinal cord neurons.41